Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Labcorp Holdings ( (LH) ) has issued an update.
On December 30, 2025, Labcorp announced it would participate in a fireside chat at the 44th Annual J.P. Morgan Healthcare Conference, scheduled for Tuesday, January 13 at 4:30 p.m. Pacific Time. The session, which will be accessible via a live audio webcast on the company’s investor relations website and archived for replay, underscores Labcorp’s ongoing efforts to engage with the investment community and highlight its role in the global diagnostics and drug development ecosystem.
The most recent analyst rating on (LH) stock is a Buy with a $308.00 price target. To see the full list of analyst forecasts on Labcorp Holdings stock, see the LH Stock Forecast page.
Spark’s Take on LH Stock
According to Spark, TipRanks’ AI Analyst, LH is a Outperform.
Labcorp Holdings demonstrates strong financial performance and strategic growth initiatives, particularly in the Diagnostics and Central Laboratories segments. While technical indicators suggest a bearish trend, the company’s focus on high-growth areas and technological innovation provides a positive outlook. Valuation metrics indicate the stock is fairly valued, with potential for growth if earnings continue to improve. Recent corporate events further support the company’s strategic direction.
To see Spark’s full report on LH stock, click here.
More about Labcorp Holdings
Labcorp Holdings Inc. (NYSE: LH) is a global leader in innovative and comprehensive laboratory services, providing diagnostics and drug development capabilities that support doctors, hospitals, pharmaceutical companies, researchers and patients. With nearly 70,000 employees serving clients in about 100 countries, the company performs more than 700 million tests annually and supported over three-quarters of the new drugs and therapeutic products approved by the U.S. Food and Drug Administration in 2024.
Average Trading Volume: 811,652
Technical Sentiment Signal: Buy
Current Market Cap: $20.97B
See more data about LH stock on TipRanks’ Stock Analysis page.